Skip to content
ClinCalc Pro
Menu
Second-generation (non-sedating) antihistamine — H1 antagonist

Fexofenadine 120mg / 180mg Tablets

Brand names: Telfast

Fexofenadine tablets are a non-sedating second-generation oral antihistamine used for allergic rhinitis and other allergic symptoms.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a selective peripheral histamine H1-receptor antagonist (the active metabolite of terfenadine) that blocks histamine-mediated allergic responses with little central nervous system penetration.

Prescribing in practice

  • It is substantially less sedating than older antihistamines, making it preferable when drowsiness must be minimised, though individuals may still occasionally be affected.
  • Absorption is reduced by aluminium- and magnesium-containing antacids and by certain fruit juices, which should be separated from the dose.
  • The higher tablet strength is generally reserved for chronic urticaria rather than routine allergic rhinitis, per the SPC.

Monitoring

Routine monitoring is not required; review symptom control and tolerability at follow-up.

Counselling the patient

  • It is usually non-drowsy, but take care driving until you know how it affects you.
  • Avoid taking it at the same time as indigestion remedies or fruit juice.
  • It can be taken regularly during your allergy season for best control.

Evidence & guidelines

Non-sedating antihistamines such as fexofenadine are recommended first-line for allergic rhinitis in UK and international (ARIA) guidance.

Reference: ARIA Guidelines; BSACI Allergic Rhinitis; Telfast SPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.